Posts tagged science
Articles and news from the latest research reports.
Study confirms mitochondrial deficits in children with autism
Children with autism experience deficits in a type of immune cell that protects the body from infection. Called granulocytes, the cells exhibit one-third the capacity to fight infection and protect the body from invasion compared with the same cells in children who are developing normally.
The cells, which circulate in the bloodstream, are less able to deliver crucial infection-fighting oxidative responses to combat invading pathogens because of dysfunction in their tiny energy-generating organelles, the mitochondria.
The study is published online in the journal Pediatrics.
“Granulocytes fight cellular invaders like bacteria and viruses by producing highly reactive oxidants, toxic chemicals that kill microorganisms. Our findings show that in children with severe autism the level of that response was both lower and slower,” said Eleonora Napoli, lead study author and project scientist in the Department of Molecular Biosciences in the UC Davis School of Veterinary Medicine. “The granulocytes generated less highly reactive oxidants and took longer to produce them.”
The researchers also found that the mitochondria in the granulocytes of children with autism consumed far less oxygen than those of the typically developing children — another sign of decreased mitochondrial function.
Mitochondria are the main intracellular source of oxygen free radicals, which are very reactive and can harm cellular structures and DNA. Cells can repair typical levels of oxidative damage. However, in the children with autism the cells produced more free radicals and were less able to repair the damage, and as a result experienced more oxidative stress. The free radical levels in the blood cells of children with autism were 1 ½ times greater than those without the disorder.
The study was conducted using blood samples of children enrolled in the Childhood Risk of Autism and the Environment (CHARGE) Study and included 10 children with severe autism age 2 to 5 and 10 age-, race- and sex-matched children who were developing typically.
In an earlier study the research team found decreased mitochondrial fortitude in another type of immune cell, the lymphocytes. Together, the findings suggest that deficiencies in the cells’ ability to fuel brain neurons might lead to some of the cognitive impairments associated with autism. Higher levels of free radicals also might contribute to autism severity.
“The response found among granulocytes mirrors earlier results obtained with lymphocytes from children with severe autism, underscoring the cross-talk between energy metabolism and response to oxidative damage,” said Cecilia Giulivi, professor in the Department of Molecular Biosciences in the UC Davis School of Veterinary Medicine and the study’s senior author.
“It also suggests that the immune response seems to be modulated by a nuclear factor named NRF2,” that controls antioxidant response to environmental factors and may hold clues to the gene-environment interaction in autism, Giulivi said.
Mouse study offers new clues to cognitive decline
New research suggests that certain types of brain cells may be “picky eaters,” seeming to prefer one specific energy source over others. The finding has implications for understanding the cognitive decline seen in aging and degenerative diseases such as Alzheimer’s and multiple sclerosis.
(Image caption: Neural stem cells differentiate into three different cell types: neurons (purple), oligodendrocytes (red), which produce axon insulation, and astrocytes (green), which also support neurons. Cell nuclei are shown in blue. Credit: Liana Roberts Stein)
Studying mice, investigators from Washington University School of Medicine in St. Louis showed that a specific energy source called NAD is important in cells responsible for maintaining the overall structure of the brain and for performing complex cognitive functions. NAD (nicotinamide adenine dinucleotide) is a molecule that harvests energy from nutrients in food and converts it into a form cells can use.
The work appears in two journal articles — in the May 8 issue of The EMBO Journal, a publication of the European Molecular Biology Organization, and in a recent issue of The Journal of Neuroscience.
“We are interested in understanding how cells make NAD and what implications that has for cellular function, especially in the context of aging and longevity,” said Shin-ichiro Imai, MD, PhD, professor of developmental biology and of medicine and senior author of both papers. “We know, for example, NAD levels decrease with age in tissues such as muscle and fat. We wanted to find out if the same is true in the brain.”
The investigators looked at two types of brain cells: adult neural stem cells, responsible for maintaining supplies of neurons and their supporting cells, and forebrain neurons, vital for performing complex cognitive tasks.
In The EMBO Journal, they reported that NAD levels decreased with age in the mouse hippocampus, a vital region of the brain for cognition. The researchers then used genetic techniques to find out what would happen when NAD manufacturing is turned off in the adult neural stem cells of the mouse brain.
“Neural stem cells are very metabolically expensive, so you might expect them to be particularly vulnerable to loss of an energy source,” said first author Liana Roberts Stein, PhD, postdoctoral researcher in Imai’s lab. “There are other energy sources for brain cells, such as glucose, but no one had ever looked at where NAD is coming from in these cells.”
According to the researchers, there are four pathways of NAD synthesis, and the scientists focused on just one. They wanted to find out whether this particular pathway — a longtime focus of Imai’s lab — is important for these cells or if the other routes could compensate.
The pathway begins with the B vitamin nicotinamide. Cells take dietary nicotinamide and, with a helper protein called Nampt, manufacture a molecule called NMN, which then is processed further to make NAD. When Stein eliminated Nampt from neural stem cells, several significant changes took place.
Levels of NAD dropped, and the neural stem cells stopped dividing; they stopped renewing themselves; and they stopped being able to create important cells that insulate axons, the “wires” that carry electrical signals throughout the brain. With less insulation, these signals slow down, impairing brain function.
Imai and Stein pointed out possible therapeutic implications of this finding, especially in light of what is known about cognitive decline in aging and certain diseases.
“Scientists have shown that with age there actually isn’t a large decrease in the total neuron population,” Stein said. “But there is quite a substantial decrease in white matter, which is primarily composed of cells that function in axon insulation. This pathway also could be relevant in conditions involving loss of cells that make this insulation, like multiple sclerosis.”
Imai and Stein also found they could prevent the loss of the neural stem cells missing Nampt by giving the mice NMN, the next molecule in the chain of events leading to NAD.
“We gave the mice NMN in their drinking water for 12 months,” Stein said. “And at the higher dose, we saw a rescue of the neural stem cell pool in aged mice.”
Imai called this finding exciting because it supports the possibility of a future NMN supplement.
“We think that NMN could convey a similar effect in people,” Imai said. “A future clinical trial for NMN will tell us if it has any efficacy in humans.”
In addition to maintaining stem cell populations and keeping the brain supplied with all its cell types, the investigators showed that NAD also is vital for the process of cognition itself.
Reporting in The Journal of Neuroscience, they showed that neurons of the mouse forebrain depend heavily on NAD in normal cognitive function. Instead of deleting Nampt in stem cells, this time Stein deleted it only in neurons of the forebrain. All other cells were normal, including those that make axon insulation.
Without Nampt and its eventual product, NAD, in forebrain neurons, the behavior of the mice changed dramatically, according to the investigators.
“The mice were really hyperactive, with a twofold increase in activity levels,” Stein said. “They also showed a loss of anxiety-like behaviors. These mice didn’t seem to sense or fear potentially threatening situations and showed fairly drastic memory defects.”
Stein pointed out that these neurons are in a region of the brain known to be particularly vulnerable to neurodegenerative conditions from Alzheimer’s disease to stroke.
“It’s possible that these neurons’ dependence on Nampt is responsible for their extreme susceptibility to these conditions,” she said. “It would be interesting to model some of these diseases in mice and see if supplementing NMN provides any benefit to their behavior or memory.”
“We haven’t done that study yet,” Imai added. “But this is the direction the entire field is going.”
(Source: news.wustl.edu)
(Image caption: In Greek mythology, Clotho – the eponym for the anti-aging factor klotho – is the Fate who spins the thread of life. Here, the goddess spins the metaphorical thread of life that is DNA, influencing lifespan and cognition. Illustration by Michael Griffin Kelley)
Better Cognition Seen with Gene Variant Carried by 1 in 5 People
A scientific team led by the Gladstone Institutes and UC San Francisco has discovered that a common form of a gene already associated with long life also improves learning and memory, a finding that could have implications for treating age-related diseases like Alzheimer’s.
The researchers found that people who carry a single copy of the KL-VS variant of the KLOTHO gene perform better on a wide variety of cognitive tests. When the researchers modeled the effects in mice, they found it strengthened the connections between neurons that make learning possible – what is known as synaptic plasticity – by increasing the action of a cell receptor critical to forming memories.
The discovery is a major step toward understanding how genes improve cognitive ability and could open a new route to treating diseases like Alzheimer’s. Researchers have long suspected that some people may be protected from the disease because of their greater cognitive capacity, or reserve. Since elevated levels of the klotho protein appear to improve cognition throughout the lifespan, raising klotho levels could build cognitive reserve as a bulwark against the disease.
“As the world’s population ages, cognitive frailty is our biggest biomedical challenge,” said Dena Dubal, MD, PhD, assistant professor of neurology, the David A. Coulter Endowed Chair in Aging and Neurodegeneration at UCSF and lead author of the study, published May 8 in Cell Reports. “If we can understand how to enhance brain function, it would have a huge impact on people’s lives.”
First to Link Between Klotho Variant and Better Cognition
Klotho was discovered in 1997 and named after the Fate from Greek mythology who spins the thread of life.
The investigators found that people who carry a single copy of the KL-VS variant of the KLOTHO gene, roughly 20 percent of the population, have more klotho protein in their blood than non-carriers. Besides increasing the secretion of klotho, the KL-VS variant may also change the action of the protein and is known to lessen age-related cardiovascular disease and promote longevity.
The team’s report is the first to link the KL-VS variant, or allele, to better cognition in humans, and buttresses these findings with genetic, electrophysiological, biochemical and behavioral experiments in mice.
The researchers tested the associations between the allele and age-related human cognition in three separate studies involving more than 700 people without dementia between the ages of 52 and 85. Altogether, it took about three years to conduct the work.
“These surprising results pave a promising new avenue of research,” said Roderick Corriveau, PhD, program director at NIH’s National Institute of Neurological Disorders and Stroke (NINDS). “Although preliminary, they suggest klotho could be used to bump up cognition for people suffering from dementia.”
Learning Better at All Stages of Life
Having the KL-VS allele did not seem to protect people from age-related cognitive decline. But overall the effect was to boost cognition, so that the middle-aged study participants began their decline from a higher point.
“Based on what was known about klotho, we expected it to affect the brain by changing the aging process,” said senior author Lennart Mucke, MD, who directs neurological research at the Gladstone Institutes and is a professor of neurology and the Joseph B. Martin Distinguished Professor of Neuroscience at UCSF. “But this is not what we found, which suggested to us that we were on to something new and different.”
To get a closer look at how the gene variant operates, the researchers used mice that were engineered to produce more of the mouse version of klotho and found that these mice learned better at all stages of life. Put through mazes, these transgenic mice were more likely to try different routes, an indication that they had superior working memory. In a test of spatial learning and memory, the mice with extra klothoperformed twice as well.
Researchers then analyzed the mouse brain tissue and found that the mice with elevated klotho had twice as many GluN2B subunits within synaptic connections. GluN2B is part of the N-methyl-D-aspartate receptor, or NMDAR, a key receptor involved in synaptic plasticity.
The researchers found more GluN2B-containing receptors in the hippocampus and frontal cortex, brain regions that support cognitive functions. When the researchers gave the mice a drug that blocks the action of these receptors, the klotho-enhanced mice lost their cognitive advantage.
Temper trap: the genetics of aggression and self-control
Everyone knows someone with a quick temper – it might even be you. And while scientists have known for decades that aggression is hereditary, there is another biological layer to those angry flare-ups: self-control.
In a paper published earlier this year in the Journal of Cognitive Neuroscience, my colleagues and I found that people who are genetically predisposed toward aggression try hard to control their anger, but have inefficient functioning in brain regions that control emotions.
In other words, self-control is, in part, biological.
Psilocybin inhibits the processing of negative emotions in the brain
When emotions are processed in a negatively biased manner in the brain, an individual is at risk to develop depression. Psilocybin, the bioactive component of the Mexican magic mushroom, seems to intervene positively in the emotion-processing mechanism. Even a small amount of the natural substance attenuates the processing of negative emotions and brightens mood as shown by UZH researchers using imaging methods.
Emotions like fear, anger, sadness, and joy enable people to adjust to their environment and react flexibly to stress and strain and are vital for cognitive processes, physiological reactions, and social behaviour. The processing of emotions is closely linked to structures in the brain, i.e. to what is known as the limbic system. Within this system the amygdala plays a central role – above all it processes negative emotions like anxiety and fear. If the activity of the amygdala becomes unbalanced, depression and anxiety disorders may develop.
Researchers at the Psychiatric University Hospital of Zurich have now shown that psilocybin, the bioactive component in the Mexican magic mushroom, influences the amygdala, thereby weakening the processing of negative stimuli. These findings could “point the way to novel approaches to treatment” comments the lead author Rainer Krähenmann on the results which have now been published in the renowned medical journal “Biological Psychiatry”.
Psilocybin inhibits the processing of negative emotions in the amygdala
The processing of emotions can be impaired by various causes and elicit mental disorders. Elevated activity of the amygdala in response to stimuli leads to the neurons strengthening negative signals and weakening the processing of positive ones. This mechanism plays an important role in the development of depression and anxiety disorders. Psilocybin intervenes specifically in this mechanism as shown by Dr. Rainer Krähenmann’s research team of the Neuropsychopharmacology and Brain Imaging Unit led by Prof. Dr. Franz Vollenweider.
Psilocybin positively influences mood in healthy individuals. In the brain, this substance stimulates specific docking sites for the messenger serotonin. The scientists therefore assumed that psilocybin exerts its mood-brightening effect via a change in the serotonin system in the limbic brain regions. This could, in fact, be demonstrated using functional magnetic resonance imaging (fMRI). “Even a moderate dose of psilocybin weakens the processing of negative stimuli by modifying amygdala activity in the limbic system as well as in other associated brain regions”, continues Krähenmann. The study clearly shows that the modulation of amygdala activity is directly linked to the experience of heightened mood.
Next study with depressive patients
According to Krähenmann, this observation is of major clinical importance. Depressive patients in particular react more to negative stimuli and their thoughts often revolve around negative contents. Hence, the neuropharmacologists now wish to elucidate in further studies whether psilocybin normalises the exaggerated processing of negative stimuli as seen in neuroimaging studies of depressed patients - and may consequently lead to improved mood in these patients.
Rainer Krähenmann considers research into novel approaches to treatment very important, because current available drugs for the treatment of depression and anxiety disorders are not effective in all patients and are often associated with unwanted side effects.
(Source: mediadesk.uzh.ch)
New study examines premature menopause and effects on later life cognition
Premature menopause is associated with long-term negative effects on cognitive function, suggests a new study published today (7 May) in BJOG: An International Journal of Obstetrics and Gynaecology (BJOG).
The average age of menopause is around 50 years in the Western World. Premature menopause refers to menopause at or before 40 years of age, this could be due to a bilateral ovariectomy, (surgically induced menopause)or non-surgical loss of ovarian function (sometimes referred to as ‘natural’ menopause).
The study, based on a sample of 4868 women, used cognitive tests and clinical dementia diagnosis at baseline and after two, four and seven years and aimed to determine whether premature menopause can have an effect on later-life cognitive function. The effects of the type of menopause, whether natural or surgical, and use of hormone treatment were also examined.
Of the 4,868 women in this study, natural menopause was reported by 79% of the women, 10% as a surgical menopause and 11% of women reported menopause due to other causes, such as radiation or chemotherapy. Around 7.6% of the women in the study had a premature menopause and a further 12.8% an early menopause (between the ages of 41 and 45 years). Over a fifth of the women used hormone treatment during the menopause.
Results show that in comparison to women who experienced menopause after the age of 50, those with a premature menopause had a more than 40% increased risk of poor performance on tasks assessing verbal fluency and visual memory and was associated with a 35% increased risk of decline in psychomotor speed (coordination between the brain and the muscles that brings about movement) and overall cognitive function over 7 years. There was no significant association with the risk of dementia.
Furthermore, both premature ovarian failure and premature surgical menopause were associated with a more than two-fold risk of poor verbal fluency. In terms of visual memory, premature ovarian failure was associated with a significantly increased risk of poor performance, and there was a similar trend for premature surgical menopause.
When the potential modifying effect of using hormone treatment at the time of premature menopause was examined, there was some evidence that it may be beneficial for visual memory, but it could increase the risk of poor verbal fluency.
Dr Joanne Ryan, Postdoctoral Research Fellow, Neuropsychiatry: Epidemiological and Clinical Research, Hospital La Colombiere, Montpellier, said:
“Both premature surgical menopause and premature ovarian failure, were associated with long-term negative effects on cognitive function, which are not entirely offset by menopausal hormone treatment.
“In terms of surgical menopause, our results suggest that the potential long-term effects on cognitive function should form part of the decision-making process when considering ovariectomy in younger women.”
Pierre Martin Hirsch, BJOG deputy editor-in-chief added:
“With the ageing population it is important to have a better understanding of the long term effects of a premature menopause on later-life cognitive function and the potential benefit from using menopausal hormone treatment.
“This study adds to the existing evidence base to suggest premature menopause can have a significant impact on cognitive function in later life which healthcare professionals must be aware of.”
(Source: eu.wiley.com)
Scientists link honeybees’ changing roles throughout their lives to brain chemistry
Scientists have been linking an increasing range of behaviors and inclinations from monogamy to addiction to animals’, including humans’, underlying biology. To that growing list, they’re adding division of labor — at least in killer bees. A report published in ACS’ Journal of Proteome Research presents new data that link the amounts of certain neuropeptides in these notorious bees’ brains with their jobs inside and outside the hive.
Mario Sergio Palma and colleagues explain that dividing tasks among individuals in a group is a key development in social behavior among Hymenoptera insects, which include bees, ants, sawflies and wasps. One of the starkest examples of this division of labor is the development of “castes,” which, through nutrition and hormones, results in long-lived queens that lay all the thousands of eggs in a colony and barren workers that forage for food and protect the hive. Bee researchers had already observed that honeybees, including Africanized Apis mellifera, better known as “killer” bees, divide tasks by age. As workers get older, their roles change from nursing and cleaning the hive to guarding and foraging. Palma’s team wanted to see whether peptides in the brain were associated with the bees’ shifting duties.
They found that the amounts of two substances varied by time and location in the brains of the honeybees in a way that mirrored the timing of their changing roles. “Thus, these neuropeptides appear to have some functions in the honeybee brain that are specifically related to the age-related division of labor,” the scientists conclude.
(Source: acs.org)
Musical training increases blood flow in the brain
Research by the University of Liverpool has found that brief musical training can increase the blood flow in the left hemisphere of our brain. This suggests that the areas responsible for music and language share common brain pathways.
Researchers from the University’s Institute of Psychology, Health and Society carried out two separate studies which looked at brain activity patterns in musicians and non-musicians.
The first study looking for patterns of brain activity of 14 musicians and 9 non-musicians whilst they participated in music and word generation tasks. The results showed that patterns in the musician’s brains were similar in both tasks but this was not the case for the non-musicians.
In the second study, brain activity patterns were measured in a different group of non-musical participants who took part in a word generation task and a music perception task.
The measurements were also taken again following half an hour’s musical training. The measurements of brain activity taken before the musical training* showed no significant pattern of correlation. However, following the training significant similarities were found.
Amy Spray, who conducted the research as part of a School of Psychology Summer Internship Scheme, said: “The areas of our brain that process music and language are thought to be shared and previous research has suggested that musical training can lead to the increased use of the left hemisphere of the brain.
This study looked into the modulatory effects that musical training could have on the use of the different sides of the brain when performing music and language tasks.”
Amy added: “It was fascinating to see that the similarities in blood flow signatures could be brought about after just half an hour of simple musical training.”
Liverpool Psychologist, Dr Georg Mayer, explained: “This suggests that the correlated brain patterns were the result of using areas thought to be involved in language processing. Therefore we can assume that musical training results in a rapid change in the cognitive mechansims utilised for music perception and these shared mechanisms are usually employed for language.”
Brain Noise Found to Nurture Synapses
A study has shown that a long-overlooked form of neuron-to-neuron communication called miniature neurotransmission plays an essential role in the development of synapses, the regions where nerve impulses are transmitted and received. The findings, made in fruit flies, raise the possibility that abnormalities in miniature neurotransmission may contribute to neurodevelopmental diseases. The findings, by researchers at Columbia University Medical Center (CUMC), were published today in the online edition of the journal Neuron.
The primary way in which neurons communicate with each another is through “evoked neurotransmission.” This process begins when an electrical signal, or action potential, is transmitted along a long, cable-like extension of the neuron called an axon. Upon reaching the axon’s terminus, the signal triggers the release of chemicals called neurotransmitters across the synapse. Finally, the neurotransmitters bind to and activate receptors of the neuron on the other side of the synapse. Neurotransmitters are packaged together into vesicles, which are released by the hundreds, if not thousands, with each action potential. Evoked neurotransmission was first characterized in the 1950s by Sir Bernard Katz and two other researchers, who were awarded the 1970 Nobel Prize in Physiology or Medicine for their efforts.
“Dr. Katz also found that even without action potentials, lone vesicles are released now and then at the synapse,” said study leader Brian D. McCabe, PhD, assistant professor of pathology and cell biology and of neuroscience in the Motor Neuron Center. “These miniature events — or minis — have been found at every type of synapse that has been studied. However, since minis don’t induce neurons to fire, people assumed they were inconsequential, just background noise.”
Recent cell-culture studies, however, have suggested that minis do have some function and even their own regulatory mechanisms. “This led us to wonder why there would be such complicated mechanisms for regulating something that was just noise,” said Dr. McCabe.
To learn more about minis, the CUMC team devised new genetic tools to selectively up- or down-regulate evoked and miniature neurotransmission in fruit flies (a commonly used model organism for neuronal function and development). This was the first study to identify a unique role for minis in an animal model.
The researchers found that when both types of neurotransmission were blocked, synapse development was abnormal. However, inhibiting or stimulating evoked neurotransmission alone had no effect on synaptic development. “But when we blocked minis, synapses failed to develop,” said Dr. McCabe, “and when we stimulated the release of more minis, synapses got bigger.”
The study also showed that minis regulate synapse development by activating a signaling pathway in neurons involving Trio and Rac1 proteins in presynaptic neurons. These proteins are also found in humans.
It remains to be seen exactly how minis are exerting their effects. “Parallel communication occurs in computer networks,” Dr. McCabe said. “Computers communicate primarily by sending bursts of data bundled into packets. But individual computers also send out pings, or tiny electronic queries, to determine if there is a connection to other computers. Similarly, neurons may be using minis to ping connected neurons, saying in effect, ‘We are connected and I am ready to communicate.’”
The researchers are currently looking into whether minis have a functional role in the mature nervous system. If so, it’s possible that defects in minis could contribute to neurodegenerative disease.
Sleep Researchers at SRI International Identify Promising New Treatment for Narcolepsy
Neuroscientists at SRI International have found that a form of baclofen, a drug used to treat muscle spasticity, works better at treating narcolepsy than the best drug currently available when tested in mice.
According to the National Institute of Neurological Disorders and Stroke (NINDS), narcolepsy, a chronic neurologic disorder characterized by excessive daytime sleepiness, is not a rare condition, but is under-recognized and under-diagnosed. It is estimated to impact 1 in 2,000 people worldwide.
In back-to-back papers published in the May 7 issue of The Journal of Neuroscience, Thomas Kilduff, Ph.D., who directs the Center for Neuroscience within SRI Biosciences, Sarah Wurts Black, Ph.D., a research scientist in the Center for Neuroscience, and colleagues present a mouse model of narcolepsy that mimics the human disorder better than other models currently in use. Kilduff, Black and the SRI team then used the new narcolepsy model alongside a standard model to investigate a novel therapeutic pathway and to identify a promising way of treating narcolepsy.
"Our work is an example of how basic research can lead to a potential new therapy for a disease," said Kilduff. His team found that a form of baclofen, R-baclofen, works in both mouse models much better than the leading FDA-approved therapeutic for narcolepsy. (Baclofen, which has been available for more than 50 years, is a chemical compound that exists as a mixture of two isomers, designated R and S.) "The next step would be to perform a study in narcoleptic patients to determine its potential for treatment of human narcolepsy."
In humans, narcolepsy onset is typically during adolescence or later, but diagnosis may take more than a decade, making it difficult to study the progression of the disease. The lack of definitive mechanisms to explain what goes awry in the brain’s ability to regulate sleep-wake cycles has consequently yielded drugs that only address the symptoms, rather than the underlying causes, of narcolepsy.
In the first of the two papers, “Conditional Ablation of Orexin/Hypocretin Neurons: A New Mouse Model for the Study of Narcolepsy and Orexin System Function,” Kilduff and Black teamed with colleagues at five institutions in Japan to generate a model of narcolepsy that better mimics the human disorder. The existing model, called “Ataxin mice,” has been available for over 10 years. Although Ataxin mice have enabled researchers to study narcolepsy, an important limitation is that these mice are born with the deficiency of the neurotransmitter hypocretin that has been implicated in causing narcolepsy, whereas the onset of human narcolepsy typically occurs after puberty.
"The mouse model developed by Dr. Kilduff and his colleagues offers a new approach to study narcolepsy and to explore potential therapies for this devastating sleep disorder. This new model allows more precise control of the timing and extent of hypocretin/orexin neuron loss, and thus may better mimic human narcolepsy," said Janet He, Ph.D., program director at the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
In collaboration with Professor Akihiro Yamanaka of Nagoya University in Japan, formerly an SRI International Fellow in Dr. Kilduff’s laboratory, the research team genetically engineered a mouse in which the hypocretin neurons could be selectively eliminated at any age simply by removal of an antibiotic in the mouse food. In the new “DTA” model, degeneration of hypocretin neurons can be initiated after puberty, causing the mice to exhibit the two major symptoms of narcolepsy: excessive daytime sleepiness and cataplexy, the brief loss of muscle tone experienced by most narcoleptics.
In the second paper, “GABAB Agonism Promotes Sleep and Reduces Cataplexy in Murine Narcolepsy,” Black, Kilduff and colleagues used the new DTA model and the Ataxin model to compare R-baclofen against gamma-hydroxybutyrate (GHB). Sodium oxybate, the sodium salt of GHB, was approved by the FDA in 2002 as the only therapeutic for narcolepsy that simultaneously alleviates cataplexy, excessive daytime sleepiness and nocturnal sleep disruption. However, it remains unclear how this drug exerts its beneficial effects.
It was suspected that GHB works by affecting brain cells that respond to a neurotransmitter known as gamma-aminobutyric acid (GABA), which primarily functions to inhibit excitability and regulate muscle tone. To study the mechanism of action of GHB, SRI Biosciences’ researchers tested R-baclofen, which blocks the GABA receptors suspected to be the target of GHB.
The research team found that R-baclofen promoted sleep time and longer bouts of wakefulness during the appropriate times for mice and also suppressed cataplexy. GHB modestly reduced cataplexy and increased sleep intensity, but did not improve other symptoms of narcolepsy to the extent that R-baclofen did. “The improvement in wakefulness that we observed after R-baclofen was a particularly unexpected and important finding,” said Black.
"R-Baclofen works better than GHB in these two mouse models, but it remains to be determined whether it will work better in humans," cautioned Kilduff. "Although baclofen is already known to be safe for use in humans, the dose that is effective for spasticity may be different than the dose of R-baclofen that has the potential to treat narcolepsy."